ADPT
Adaptive Biotechnologies Corp

4,281
Mkt Cap
$2.57B
Volume
832,034.00
52W High
$17.89
52W Low
$4.27
PE Ratio
-20.76
ADPT Fundamentals
Price
$16.90
Prev Close
$17.12
Open
$17.01
50D MA
$14.24
Beta
1.97
Avg. Volume
2M
EPS (Annual)
-$1.08
P/B
14.32
Rev/Employee
$289,106.62
Loading...
Loading...
News
all
press releases
IQVIA Gears Up to Report Q3 Earnings: What's in the Cards?
IQV readies its Q3 report, with revenues and EPS expected to rise on biopharma strength and cost control despite muted beat odds.
Zacks·6d ago
News Placeholder
More News
News Placeholder
LLY Gets EU Approval for Alzheimer's Drug & FDA Nod to Cancer Therapy
Eli Lilly secures EU approval for Alzheimer's drug Kisunla and gains FDA nod to breast cancer therapy Inluriyo.
Zacks·1mo ago
News Placeholder
Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year?
Here is how Adaptive Biotechnologies (ADPT) and Biorestorative Therapies, Inc. (BRTX) have performed compared to their sector so far this year.
Zacks·1mo ago
News Placeholder
CRSP & Sirius Begin Dosing in Thromboembolic Disorder Study in EU
CRISPR Therapeutics and Sirius dose the first patient in a phase II study of SRSD107 for thromboembolic disorders in Europe.
Zacks·1mo ago
News Placeholder
NTLA Completes Enrollment in Pivotal Study on HAE Candidate, Stock Up
Intellia shares surge nearly 30% as the company completes enrollment in its pivotal phase III HAELO study on lonvo-z for hereditary angioedema.
Zacks·1mo ago
News Placeholder
Krystal Biotech Stock Up on FDA Nod to Vyjuvek Label Update
KRYS shares jump after the FDA expands Vyjuvek's label to include DEB patients from birth, with added at-home use flexibility.
Zacks·1mo ago
News Placeholder
FDA Accepts Corcept's NDA for Relacorilant in Ovarian Cancer
CORT's NDA for relacorilant in platinum-resistant ovarian cancer gains FDA acceptance, with a decision expected by July 2026.
Zacks·2mo ago
News Placeholder
IONS Up on FDA's Breakthrough Tag for ION582 in Angelman Syndrome
Ionis jumps as FDA grants Breakthrough Therapy status to ION582 for treating Angelman syndrome, with the phase III study now underway.
Zacks·2mo ago
News Placeholder
Is Cardinal Health (CAH) Stock Outpacing Its Medical Peers This Year?
Here is how Cardinal Health (CAH) and Adaptive Biotechnologies (ADPT) have performed compared to their sector so far this year.
Zacks·2mo ago
News Placeholder
AQST Stock Up as FDA Skips Advisory Meeting to Discuss Anaphylm NDA
Aquestive Therapeutics shares surge after FDA skips advisory meeting on Anaphylm NDA, keeping its January 2026 action date intact.
Zacks·2mo ago

Latest ADPT News

View

Advertisement|Remove ads.

Advertisement|Remove ads.